Drug carriers play a critical role for the loading and the release of the drug. A promising frontier is represented by a new class of innovative medicines that represents directional transport vehicles "drug delivery" and consist of assembled structures carrier (nano)-drug. Silica-based materials, nontoxic, biocompatible, have been used as adjuvant and excipient in pharmaceutical technology. In this class of compounds, the mesoporous materials, such as MCM41, SBA-15 and hexagonal mesoporous silica, have been investigated for medication and drug delivery due to their properties. In fact, these materials show a large specific pore volume made up of regular pores having a diameter in the nanometer range, which facilitates controlled delivery of pharmaceutical drugs. Recently, a new anticancer drug, the cis-[PtCl2(DMSO)HL]·2DMSO, where HL = 7-amino-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid, has been synthesized and tested [1]. It exhibited a very marked biological activity on HepG2 hepatocarcinoma cells while under identical conditions it did not affect normal immortalized human liver cells (Chang Liver cells). The scope of this work is to design and investigate a new material constituted by this drug and by mesoporous MCM41 or the MCM41 functionalized with amino group as support. The choice to use the functionalized MCM41 is to investigate the rule of the amino group in the release. The MCM41 was functionalized with amino groups using the grafting method. The incorporation of the drug in the two mesoporous was performed by mixing the two components in chloroform. A detailed characterization of the materials was made using X-ray Diffraction (XRD), FT-IR Spectroscopy, and 29Si Cross Polarization - Magic Angle Spinning NMR (29Si {1H} CP - MAS NMR). The release was evaluated at pH 7.4 and T=37°C in a phosphate buffer solution (PBS) in order to simulate the cellular conditions. [1] Rubino S., Di Stefano V., Attanzio A., Tesoriere L., Girasolo M.A., Nicolò F., Bruno G., Inorganica Chimica Acta 418 (2014) 112-118

Saladino, M.L., Colomba, P., Rubino, S., Girasolo, M.A., Demirbag, C., Caponetti, E. (2015). Incorporation of Pt(II) complex with [amino-2(methylthio)(1,2,4)triazole-(1,5-a)pyrimidine-6-carboxylic-acid] ligand in MCM41 for controlled release. In 3° Meeting IBIM-CNR STEBICEF-UNIPA (pp.NT7).

Incorporation of Pt(II) complex with [amino-2(methylthio)(1,2,4)triazole-(1,5-a)pyrimidine-6-carboxylic-acid] ligand in MCM41 for controlled release

SALADINO, Maria Luisa;RUBINO, Simona;GIRASOLO, Maria Assunta;CAPONETTI, Eugenio
2015-01-01

Abstract

Drug carriers play a critical role for the loading and the release of the drug. A promising frontier is represented by a new class of innovative medicines that represents directional transport vehicles "drug delivery" and consist of assembled structures carrier (nano)-drug. Silica-based materials, nontoxic, biocompatible, have been used as adjuvant and excipient in pharmaceutical technology. In this class of compounds, the mesoporous materials, such as MCM41, SBA-15 and hexagonal mesoporous silica, have been investigated for medication and drug delivery due to their properties. In fact, these materials show a large specific pore volume made up of regular pores having a diameter in the nanometer range, which facilitates controlled delivery of pharmaceutical drugs. Recently, a new anticancer drug, the cis-[PtCl2(DMSO)HL]·2DMSO, where HL = 7-amino-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylic acid, has been synthesized and tested [1]. It exhibited a very marked biological activity on HepG2 hepatocarcinoma cells while under identical conditions it did not affect normal immortalized human liver cells (Chang Liver cells). The scope of this work is to design and investigate a new material constituted by this drug and by mesoporous MCM41 or the MCM41 functionalized with amino group as support. The choice to use the functionalized MCM41 is to investigate the rule of the amino group in the release. The MCM41 was functionalized with amino groups using the grafting method. The incorporation of the drug in the two mesoporous was performed by mixing the two components in chloroform. A detailed characterization of the materials was made using X-ray Diffraction (XRD), FT-IR Spectroscopy, and 29Si Cross Polarization - Magic Angle Spinning NMR (29Si {1H} CP - MAS NMR). The release was evaluated at pH 7.4 and T=37°C in a phosphate buffer solution (PBS) in order to simulate the cellular conditions. [1] Rubino S., Di Stefano V., Attanzio A., Tesoriere L., Girasolo M.A., Nicolò F., Bruno G., Inorganica Chimica Acta 418 (2014) 112-118
17-dic-2015
3° Meeting IBIM- CNR STEBICEF-UNIPA
Palermo, CNR
17-18 Dicembre
1
A stampa
Saladino, M.L., Colomba, P., Rubino, S., Girasolo, M.A., Demirbag, C., Caponetti, E. (2015). Incorporation of Pt(II) complex with [amino-2(methylthio)(1,2,4)triazole-(1,5-a)pyrimidine-6-carboxylic-acid] ligand in MCM41 for controlled release. In 3° Meeting IBIM-CNR STEBICEF-UNIPA (pp.NT7).
Proceedings (atti dei congressi)
Saladino, ML; Colomba, P; Rubino, S; Girasolo, MA; Demirbag, C; Caponetti, E
File in questo prodotto:
File Dimensione Formato  
Abstract 2015.pdf

accesso aperto

Descrizione: Abstract
Dimensione 579.76 kB
Formato Adobe PDF
579.76 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/174021
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact